Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study

[1]  O. Landgren,et al.  Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes , 2017, Journal of internal medicine.

[2]  O. Landgren,et al.  A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival. , 2016, Seminars in oncology.

[3]  J. Hou,et al.  Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma , 2016, Chinese journal of cancer.

[4]  Wenming Chen,et al.  Effects and mechanism of arsenic trioxide in combination with rmhTRAIL in multiple myeloma. , 2016, Experimental Hematology.

[5]  Wenming Chen.  [The guidelines for the diagnosis and management of multiple myeloma in China (2015 revision) : interpretation of the treatment of relapsing and refractory multiple myeloma]. , 2016, Zhonghua nei ke za zhi.

[6]  H. Deng,et al.  Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line , 2015, OncoTargets and therapy.

[7]  J. Hou,et al.  Transiently Elevated AST/LDH Are Associated with Clinical Response to Recombinant Circularly Permuted TRAIL (CPT) Plus Thalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma , 2014 .

[8]  J. Hou,et al.  A multicenter, open‐label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma , 2014, American journal of hematology.

[9]  A. Krishnan,et al.  Multiple myeloma, version 1.2013. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  J. Hou,et al.  Phase Ib Study of Recombinant Circularly Permuted TRAIL (CPT) in Relapsed or Refractory multiple Myeloma Patients , 2012 .

[11]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[12]  B. Barlogie,et al.  Erratum: International uniform response criteria for multiple myeloma (Leukemia (2006) vol. 20 (1467-1473) 10.1038/sj.leu.2404284) , 2006 .

[13]  M. Beksac,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[14]  F. Fang,et al.  Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand , 2005, Acta Pharmacologica Sinica.

[15]  A. Anagnostopoulos,et al.  Thalidomide and dexamethasone for resistant multiple myeloma , 2003, British journal of haematology.

[16]  K. Totpal,et al.  Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. , 2001, The Journal of pharmacology and experimental therapeutics.

[17]  M. Dimopoulos,et al.  Thalidomide and dexamethasone combination for refractory multiple myeloma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  A. Palumbo,et al.  Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. , 2001, Haematologica.

[19]  S. Jagannath,et al.  CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.